Sarepta Therapeutics Inc (SRPT)
154.20
-2.55
(-1.63%)
USD |
NASDAQ |
Jul 02, 16:00
154.01
-0.19
(-0.12%)
After-Hours: 06:53
Sarepta Therapeutics SG&A Expense (Annual): 481.87M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 481.87M |
| December 31, 2022 | 451.42M |
| December 31, 2021 | 282.66M |
| December 31, 2020 | 317.88M |
| December 31, 2019 | 284.81M |
| December 31, 2018 | 207.76M |
| December 31, 2017 | 122.68M |
| December 31, 2016 | 81.20M |
| December 31, 2015 | 75.04M |
| December 31, 2014 | 49.32M |
| December 31, 2013 | 31.59M |
| December 31, 2012 | 14.63M |
| December 31, 2011 | 16.06M |
| December 31, 2010 | 14.38M |
| Date | Value |
|---|---|
| December 31, 2009 | 8.696M |
| December 31, 2008 | 11.47M |
| December 31, 2007 | 9.332M |
| December 31, 2006 | 7.753M |
| December 31, 2005 | 5.182M |
| December 31, 2004 | 4.736M |
| December 31, 2003 | 4.559M |
| December 31, 2002 | 3.764M |
| December 31, 2001 | 3.358M |
| December 31, 2000 | 2.270M |
| December 31, 1999 | 1.70M |
| December 31, 1998 | 1.60M |
| December 31, 1997 | 1.30M |
| December 31, 1996 | 0.60M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
282.66M
Minimum
2021
481.87M
Maximum
2023
363.73M
Average
317.88M
Median
2020
SG&A Expense (Annual) Benchmarks
| Pfizer Inc | 14.77B |
| Gilead Sciences Inc | 6.09B |
| Johnson & Johnson | 20.11B |
| Catalyst Pharmaceuticals Inc | 133.71M |
| Vertex Pharmaceuticals Inc | 1.137B |